Overcoming docetaxel resistance in prostate cancer: a perspective review
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming docetaxel resistance in prostate cancer: a perspective review
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 4, Issue 6, Pages 329-340
Publisher
SAGE Publications
Online
2012-06-23
DOI
10.1177/1758834012449685
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
- (2017) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate
- (2011) Grinu Mathew et al. CELL CYCLE
- New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
- (2011) G. Attard et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)
- (2011) C. Parker et al. EUROPEAN JOURNAL OF CANCER
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Class III -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
- (2010) G. Ploussard et al. CANCER RESEARCH
- Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
- (2010) M. Yamaoka et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy
- (2010) Xi-wei Ding et al. LIFE SCIENCES
- Drug resistance in metastatic castration-resistant prostate cancer
- (2010) Bostjan Seruga et al. Nature Reviews Clinical Oncology
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
- (2009) L. Zhao et al. CANCER RESEARCH
- Ixabepilone: targeting III-tubulin expression in taxane-resistant malignancies
- (2009) C. Dumontet et al. MOLECULAR CANCER THERAPEUTICS
- Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
- (2009) Catherine Sánchez et al. PROSTATE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy
- (2008) Richard D. Sowery et al. BJU INTERNATIONAL
- Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival
- (2008) Erin R. Gardner et al. BJU INTERNATIONAL
- C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer
- (2008) Tomasz M. Beer et al. CANCER
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel
- (2008) T. M. Sissung et al. CLINICAL CANCER RESEARCH
- Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
- (2008) Jean-Pascal Machiels et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Change in Markers of Bone Metabolism with Chemotherapy for Advanced Prostate Cancer: Interleukin-6 Response Is a Potential Early Indicator of Response to Therapy
- (2008) Kathleen M. Woods Ignatoski et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer
- (2008) Lye Lin Ho et al. PROSTATE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More